Okamura, Yukiyasu, Boku, Narikazu, Ghaneh, Paula, Greenhalf, William 
ORCID: 0000-0002-1865-3195, Yasukawa, Satoru, Narimatsu, Hiroto, Fukutomi, Akira, Konishi, Masaru, Morinaga, Soichiro, Toyama, Hirochika et al (show 12 more authors)
(2021)
Concordance of human equilibrative nucleoside transporter‐1 expressions between murine (
10D7G2
) and rabbit (
SP120
) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the
JASPAC
01 trial.
Cancer Reports, 5 (5).
e1507-.
Abstract
<h4>Background</h4>Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. However, predictive values of immunohistochemical hENT1 expression may differ according to the antibodies, 10D7G2 and SP120.<h4>Aim</h4>We aimed to investigate the concordance of immunohistochemical hENT1 expression between the two antibodies and prognosis.<h4>Methods</h4>The subjects of this study were totally 332 whose formalin-fixed paraffin-embedded specimens and/or unstained sections were obtained. The individual H-scores and four classifications according to the staining intensity were applied for the evaluation of hENT1 expression by 10D7G2 and SP120, respectively.<h4>Results</h4>The highest concordance rate (79.8%) was obtained when the cut-off between high and low hENT1 expression using SP120 was set between moderate and strong. There were no correlations of hENT1 mRNA level with H-score (p = .258). Although the hENT1 mRNA level was significantly different among four classifications using SP120 (p = .011), there was no linear relationship among them. Multivariate analyses showed that adjuvant GEM was a significant predictor of the patients with low hENT1 expression using either 10D7G2 (Hazard ratio [HR] 2.39, p = .001) or SP120 (HR 1.84, p < .001). In contrast, agent for adjuvant chemotherapy was not significant predictor for the patients with high hENT1 expression regardless of the kind of antibody.<h4>Conclusion</h4>The present study suggests that the two antibodies for evaluating hENT1 expression are equivalent depending on the cut-off point and suggests that S-1 is the first choice of adjuvant chemotherapy for pancreatic cancer with low hENT1 expression, whereas either S-1 or GEM can be introduced for the pancreatic cancer with high hENT1 expression, no matter which antibody is used.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | gemcitabine, human equilibrative nucleoside transporter-1, pancreatic cancer, SP120 |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 19 Jan 2022 10:27 |
| Last Modified: | 23 Sep 2023 01:27 |
| DOI: | 10.1002/cnr2.1507 |
| Open Access URL: | https://doi.org/10.1002/cnr2.1507 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3147180 |
Dimensions
Dimensions
